Weight Loss Results
Mounjaro Before and After Results: What Weight Loss Can You Expect?
Quick Answer: Clinical trial data from SURMOUNT-1 shows that patients on Mounjaro 15 mg lose an average of 22.5% of body weight over 72 weeks — more than any other currently licensed weight management treatment. In practical terms, a patient starting at 100 kg could expect to lose approximately 8–11 kg within three months, 13–15 kg by six months and up to 22 kg within 72 weeks. Results vary by dose level, starting weight, adherence and lifestyle factors. This page explains the full evidence base and what realistic, personalised results look like.22.5%avg weight loss at 15 mg (SURMOUNT-1, 72 wks)
~7–9%typical weight loss at 3 months
2,539SURMOUNT-1 participants
SURMOUNT-1 Trial Data
Mounjaro Clinical Trial Results: The Evidence Base
The weight loss data for Mounjaro comes primarily from the SURMOUNT (Tirzepatide Once Weekly for Adults with Obesity or Overweight) clinical trial programme — a series of large randomised controlled trials that form the evidence base for MHRA approval and NICE recommendation (TA1026).
The landmark SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI of 30 or above, or 27 or above with at least one weight-related comorbidity) without type 2 diabetes. Participants received tirzepatide at 5 mg, 10 mg or 15 mg, or placebo, alongside lifestyle intervention for 72 weeks. The results were extraordinary by any standard — producing weight loss that had previously been achievable only through bariatric surgery.
SURMOUNT-1: Headline Outcomes at 72 Weeks
SURMOUNT-5: Head-to-Head With Wegovy
The SURMOUNT-5 trial — the first head-to-head comparison of tirzepatide and semaglutide 2.4 mg (Wegovy) in adults with obesity — confirmed Mounjaro's superiority. Participants on tirzepatide achieved approximately 47% more weight loss than those on semaglutide over 72 weeks. Average weight loss was approximately 20.2% with tirzepatide versus 13.7% with semaglutide — a clinically meaningful and statistically significant difference. This trial positions Mounjaro as the most effective licensed weight management injection currently available in the UK.
What the Data Means in Practice
Clinical trial averages represent population means across thousands of participants with diverse starting weights and metabolic profiles. Individual results will vary. Some patients achieve substantially more than the average; others achieve less. The 22.5% figure is a central estimate from a clinical trial population — understanding this context is essential for setting realistic expectations. What the data unambiguously shows, however, is that Mounjaro produces weight loss outcomes that are clinically transformative at a population level.
| Outcome Measure | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| Mean weight loss | 15.0% | 19.5% | 22.5% | 3.1% |
| Weight loss of ≥5% | 85% | 89% | 91% | 35% |
| Weight loss of ≥10% | 69% | 79% | 83% | 16% |
| Weight loss of ≥15% | 48% | 67% | 73% | 7% |
| Weight loss of ≥20% | 28% | 50% | 57% | 2% |
| Mean absolute weight loss | ~15.4 kg | ~19.8 kg | ~21.8 kg | ~3.2 kg |
| Waist circumference reduction | ~14.0 cm | ~17.0 cm | ~18.4 cm | ~3.3 cm |
Month by Month
Month 1 Mounjaro Results: What to Expect
The first month of Mounjaro treatment is the 2.5 mg tolerability phase. This dose is not designed for maximum therapeutic effect — it is designed to introduce tirzepatide's dual GLP-1/GIP mechanism gradually while the body adapts. Weight loss expectations at this stage should be modest.
Typical Weight Loss in Month 1
Most patients lose between 2 and 5 kg in their first month of Mounjaro treatment, depending on starting weight and any concurrent dietary changes. Patients with higher starting weights tend to see larger absolute losses even at sub-therapeutic doses. Some patients report minimal scale movement in month one — which is entirely normal at 2.5 mg and does not indicate that treatment is not working.
What many patients notice before significant scale weight change is a meaningful shift in appetite. Within the first one to two weeks, food cravings reduce, portion sizes decrease spontaneously, and the persistent background preoccupation with food that many patients describe begins to quieten. These early signals reflect tirzepatide's GLP-1 and GIP receptor activity and are reliable early indicators that the drug is working as intended.
Body Changes Before the Scales
Some patients notice changes in how clothes fit, in bloating and in energy levels within the first two to three weeks — before any significant scale weight loss. These early physical changes reflect shifts in fluid balance, reduced calorie intake and early fat mobilisation. Patients who are exercising alongside Mounjaro treatment may also experience body composition improvements in terms of reduced fat mass that are not immediately reflected in total body weight.
Month 1 Reality Check: If you have lost only 2 kg in your first month on Mounjaro, this is normal and does not indicate treatment is not working. The 2.5 mg starting dose is a tolerability phase. Meaningful therapeutic weight loss builds through the escalation schedule and accelerates significantly from month three onwards.
Month 3 Mounjaro Results: The First Milestone
Three months is the first clinically meaningful milestone for Mounjaro patients. By this point, most patients will have reached the 7.5 mg dose — the level at which dual GLP-1/GIP agonism produces near-maximum appetite suppression for many patients. Cumulative weight loss at this stage is substantially higher than with Wegovy at the equivalent timepoint, reflecting Mounjaro's greater potency.
Typical Weight Loss at 3 Months
Analysis of SURMOUNT trial data at approximately week 12 suggests that patients on tirzepatide typically lose between 7% and 9% of their starting body weight within the first three months. For a patient starting at 100 kg, this equates to 7–9 kg. For a patient starting at 120 kg, losses of 8–11 kg are consistent with this range. These figures are noticeably higher than the 5–7% typically reported for Wegovy at the same timepoint.
Approximately 60–65% of patients achieve a 5% weight loss threshold by week 12 in SURMOUNT trials — a benchmark associated with meaningful improvements in blood pressure, blood glucose, cholesterol and joint load.
How Quickly Does Mounjaro Work?
Mounjaro begins producing its effects from the first injection — GLP-1 and GIP receptor activity increases within hours of the first dose. The subjective experience of reduced appetite and food preoccupation typically begins within the first one to two weeks, even at the 2.5 mg starting dose. However, clinically significant weight loss is a cumulative process that builds across the escalation schedule. The most dramatic weekly weight reductions typically occur between months three and six, as the dose approaches and reaches the 10–15 mg range.
Month 6 Mounjaro Results: Significant Transformation
Six months into Mounjaro treatment, most patients have been at or near the 15 mg maintenance dose for approximately one to two months. This is the period when Mounjaro's results most clearly diverge from other treatments — the combination of near-maximum dual agonism and cumulative weight loss produces outcomes that are typically well above the 10% mark that represents a transformative threshold in clinical obesity management.
Typical Weight Loss at 6 Months
SURMOUNT-1 data at approximately week 28 (close to six months) demonstrates average weight loss approaching 13% of baseline body weight for the trial overall, with the 15 mg group tracking toward 16–18% by this timepoint. For a 100 kg patient, this represents approximately 13–18 kg of weight loss. For a 130 kg patient, losses of 17–23 kg are consistent with this range at the highest dose.
Health Improvements Alongside Weight Loss
Six months of Mounjaro treatment produces health improvements that extend significantly beyond weight alone. The most commonly reported and clinically measured improvements at this stage include:
- Blood pressure reduction — systolic blood pressure improvements of 6–10 mmHg are typical
- Blood glucose — meaningful improvements in fasting glucose and HbA1c, particularly in patients with pre-diabetes or type 2 diabetes
- Lipid profiles — reductions in triglycerides and improvements in HDL cholesterol
- Waist circumference — average reductions of 12–18 cm, reflecting substantial visceral fat loss
- Sleep quality — particularly in patients with weight-related sleep apnoea
- Joint pain — reduced load through weight-bearing joints with significant pain relief reported
- Energy and stamina — most patients report substantially improved energy by month six
| Metric | Mounjaro 15 mg | Wegovy 2.4 mg |
|---|---|---|
| Average weight loss | ~16–18% | ~10–11% |
| Achievement of ≥10% loss | ~75% | ~55% |
| Waist circumference change | ~16 cm | ~10 cm |
| Blood pressure (systolic) | ~8 mmHg | ~5 mmHg |
Month 12 Mounjaro Results: Full Treatment Effect
Twelve months represents the point at which Mounjaro's cumulative weight loss effect is most comprehensively established. SURMOUNT-1 ran to 72 weeks (approximately 16 months), but the 52-week data provides a clinically relevant benchmark. By this point, patients on the highest dose have typically achieved weight loss outcomes comparable to or exceeding those of bariatric surgery in historical series.
Typical Weight Loss at 12 Months
At 12 months, patients on tirzepatide 15 mg in SURMOUNT-1 had achieved approximately 20–22% weight loss from baseline on average. More than half had lost 20% or more, and over one in three had lost 25% or more. These figures represent a step change from previous licensed weight management treatments and reflect the clinical significance of GIP receptor co-agonism alongside GLP-1.
SURMOUNT-4: Withdrawal Data
The SURMOUNT-4 trial provides important context on what happens when Mounjaro is stopped. Patients who discontinued tirzepatide after 36 weeks of treatment regained approximately two-thirds of their lost weight within 88 weeks of stopping — consistent with findings from the equivalent Wegovy withdrawal trial (STEP 4). This underscores that Mounjaro is a long-term treatment for a chronic condition, not a finite course, and that sustained results require continued treatment.
| Starting Weight | 5% Loss | 10% Loss | 20% Loss (avg) | 25% Loss |
|---|---|---|---|---|
| 80 kg | 4 kg → 76 kg | 8 kg → 72 kg | 16 kg → 64 kg | 20 kg → 60 kg |
| 100 kg | 5 kg → 95 kg | 10 kg → 90 kg | 20 kg → 80 kg | 25 kg → 75 kg |
| 120 kg | 6 kg → 114 kg | 12 kg → 108 kg | 24 kg → 96 kg | 30 kg → 90 kg |
| 140 kg | 7 kg → 133 kg | 14 kg → 126 kg | 28 kg → 112 kg | 35 kg → 105 kg |
Results Timeline
Mounjaro Weight Loss Timeline at a Glance
The milestone cards below summarise expected Mounjaro results at each key timepoint, based primarily on SURMOUNT-1 data at the 15 mg dose level.
Month 1~3–4%~3–5 kgEarly appetite change
Month 3~7–9%~7–11 kgNoticeable progress
Month 6~13–16%~12–18 kgStrong results
Month 12~20–22%~18–24 kgFull treatment effect
Maximising Results
Factors That Affect Mounjaro Results
SURMOUNT trial averages are population means — individual results vary considerably. Understanding the factors that influence response helps patients maximise their own outcomes.
Dose Level Reached
The single largest determinant of Mounjaro outcome after adherence is the maintenance dose reached. SURMOUNT-1 data shows a clear dose-response relationship: 15 mg outperforms 10 mg, which outperforms 5 mg, at every efficacy endpoint. Patients who complete the full escalation and reach 15 mg achieve the best results. Those who remain at lower doses due to tolerability or cost will still achieve clinically meaningful weight loss, but at a lower average rate.
Starting Weight
Patients with higher starting weights lose greater absolute amounts of weight, though percentage loss is broadly consistent across weight categories. A patient starting at 140 kg who achieves 22% loss will lose approximately 31 kg; a patient starting at 90 kg achieving the same percentage loses approximately 20 kg. Both are extraordinary outcomes. Patients with BMIs at the lower eligibility threshold (27–30) may experience a somewhat slower initial weight loss trajectory.
Diet Quality
Mounjaro reduces appetite but does not change what patients choose to eat. Patients who use the reduced appetite to improve diet quality — increasing protein and fibre, reducing ultra-processed foods and alcohol — consistently achieve better outcomes than those who continue prior eating patterns at a smaller volume. The drug creates the conditions for better choices; the patient makes them.
Exercise and Muscle Preservation
Resistance training is the most important single exercise intervention for optimising Mounjaro outcomes. At the level of weight loss Mounjaro produces — up to 20–25% of body weight — a meaningful proportion of lost weight can come from lean muscle mass without adequate protein intake and resistance exercise. Preserving and building muscle mass sustains metabolic rate, improves body composition at any given scale weight, and significantly reduces the risk of weight regain if treatment is eventually discontinued.
Metabolic Health at Baseline
Patients with pre-existing insulin resistance, PCOS, hypothyroidism (particularly if undertreated) or type 2 diabetes may find that weight loss progresses more slowly in the early months. These conditions do not prevent Mounjaro from working — SURMOUNT-2 specifically in type 2 diabetes patients showed excellent outcomes — but they may shift the weight loss trajectory relative to the broader trial population.
Adherence and Consistency
Consistent weekly injection without missed doses is essential for maximising Mounjaro outcomes. Mounjaro's half-life of approximately five days means that blood concentrations fall more rapidly between doses than with semaglutide — making consistency particularly important for sustained appetite suppression and weight loss momentum.
Common Mistakes That Affect Mounjaro Results
| Common Mistake | Why It Slows Results | What to Do Instead |
|---|---|---|
| Eating through nausea | Overrides the satiety signal Mounjaro is trying to establish, keeping calorie intake higher than the drug intends. | Eat only when genuinely hungry and stop when comfortable — trust the physiological cue. |
| Choosing high-calorie liquids | Calories from alcohol, sugary drinks and full-fat lattes bypass satiety signals easily and are frequently overlooked. | Stick to water, herbal teas and low-calorie drinks. Minimise alcohol throughout treatment. |
| Skipping protein | Rapid weight loss without adequate protein leads to muscle loss, reducing metabolic rate and worsening long-term body composition. | Aim for 1.2–1.5 g of protein per kg of body weight daily from lean sources. |
| Stopping treatment early | SURMOUNT-4 showed that two-thirds of lost weight is regained within 88 weeks of stopping. Early discontinuation abandons the full treatment benefit. | Treat Mounjaro as long-term. Discuss any planned discontinuation with your prescribing pharmacist. |
| Missing injections | Mounjaro's shorter half-life vs Wegovy means blood levels fall more quickly — missed doses weaken appetite suppression faster. | Set a weekly reminder. If a dose is missed by more than 4 days, skip and resume on the usual day. |
| Not exercising | Without resistance training, a higher proportion of weight lost comes from muscle rather than fat, worsening metabolic outcomes. | Incorporate resistance training 2–3 times per week alongside Mounjaro treatment. |
Illustrative Examples
Typical Mounjaro Weight Loss Examples
The following examples are based on SURMOUNT-1 trial averages at the 15 mg dose level and are illustrative rather than individual patient accounts.
Example A: Starting weight 95 kg, BMI 33
3 months: 87 kg (lost ~8 kg, ~8.4%)
6 months: 82 kg (lost ~13 kg, ~13.7%)
12 months: 74 kg (lost ~21 kg, ~22.1%)
Example B: Starting weight 115 kg, BMI 37
3 months: 105 kg (lost ~10 kg, ~8.7%)
6 months: 99 kg (lost ~16 kg, ~13.9%)
12 months: 90 kg (lost ~25 kg, ~21.7%)
Example C: Starting weight 135 kg, BMI 44
Based on SURMOUNT-1 15 mg average outcomes. Individual results will vary.
3 months: 123 kg (lost ~12 kg, ~8.9%)
6 months: 116 kg (lost ~19 kg, ~14.1%)
12 months: 105 kg (lost ~30 kg, ~22.2%)
Key Questions
Key Questions Answered
How much weight can you lose on Mounjaro?
Clinical trial data from SURMOUNT-1 shows that patients on tirzepatide 15 mg lose an average of approximately 22.5% of body weight over 72 weeks — the highest average weight loss of any currently licensed injectable weight management treatment. For a 100 kg patient, this equates to approximately 22 kg over 16 months. More than half of participants at the highest dose lost 20% or more, and over one in three lost 25% or more. Individual results depend on starting weight, dose level reached, diet quality, exercise and adherence.
What are realistic Mounjaro results?
Realistic Mounjaro results for a patient completing the full escalation to 15 mg are: approximately 7–9% weight loss by month three, 13–16% by month six and 20–22% by month twelve. For a patient starting at 100 kg, this means approximately 7–9 kg by month three, 13–16 kg by six months and 20–22 kg within a year. These are clinical trial averages — some patients achieve more, some less. Patients who combine Mounjaro with improved dietary quality, adequate protein intake and regular resistance exercise consistently achieve outcomes at or above the trial average.
How quickly does Mounjaro work?
Mounjaro begins producing biological effects within the first week of treatment — GLP-1 and GIP receptor activity increases from the first injection. Most patients notice a meaningful reduction in appetite and food cravings within one to two weeks, even at the 2.5 mg starting dose. Significant weight loss builds across the escalation schedule and accelerates most notably between months three and six as the dose approaches and reaches the 10–15 mg range. Mounjaro is not a rapid weight loss solution — it is a long-term treatment that produces clinically transformative results when used consistently over 12 months or more.
FAQs
Frequently Asked Questions: Mounjaro Results
Most patients lose between 7% and 9% of their starting body weight within the first three months of Mounjaro treatment. For a patient starting at 100 kg, this means approximately 7–9 kg. For someone starting at 120 kg, closer to 8–11 kg. These figures are notably higher than comparable Wegovy data at the same timepoint.
Head-to-head data from the SURMOUNT-5 trial shows that Mounjaro produces approximately 47% more weight loss than Wegovy in adults with obesity. Average weight loss was approximately 20.2% with tirzepatide versus 13.7% with semaglutide over 72 weeks. For patients whose primary goal is maximum weight loss, Mounjaro represents the stronger clinical choice.
Yes. SURMOUNT-1 data shows meaningful weight loss at all three dose levels studied: approximately 15% at 5 mg, 19.5% at 10 mg and 22.5% at 15 mg over 72 weeks. Even the lowest studied maintenance dose (5 mg) produces results that significantly exceed those of semaglutide in absolute terms.
Appetite reduction begins within the first one to two weeks even at the 2.5 mg starting dose. Significant weight loss builds across the escalation schedule, with the most rapid weekly reductions typically occurring between months three and six as the dose approaches 10–15 mg.
Weight loss typically slows as patients approach their new metabolic equilibrium, usually after six to twelve months of maintenance treatment. A plateau does not mean Mounjaro has stopped working — it means the body is adapting. Reviewing dietary quality, protein intake and activity levels with your clinician is the appropriate response.
Yes — over one in three participants in SURMOUNT-1 at the 15 mg dose achieved 25% or more weight loss at 72 weeks. This is achievable but not guaranteed. Higher starting weights, consistent adherence to 15 mg and strong dietary practices are associated with the greatest weight loss.
Mounjaro is considered clinically effective if you have lost at least 5% of your starting weight by around week 16 of treatment, consistent with NICE TA1026 monitoring criteria. Most patients notice appetite reduction much earlier — within one to two weeks — which is the first clinical indicator that the medication is active.
SURMOUNT-4 trial data demonstrates that patients who discontinued tirzepatide regained approximately two-thirds of their lost weight within 88 weeks of stopping. This is consistent with findings across the GLP-1 drug class and reflects the chronic nature of obesity. Stopping treatment should be a planned clinical decision made with your prescribing pharmacist.
SURMOUNT trial data shows broadly comparable percentage weight loss outcomes across sexes, though absolute losses reflect starting weight differences. Women with PCOS or perimenopausal hormonal changes may experience a slightly less linear trajectory — this is worth discussing with your prescribing clinician.
Yes. The SURMOUNT trials included lifestyle counselling alongside medication. Patients who actively improve diet quality and incorporate resistance training consistently achieve results at or above the trial average. The medication creates the physiological conditions — dietary and exercise choices determine how fully those conditions are used.
Mounjaro's 15 mg average weight loss of 22.5% at 72 weeks approaches the outcomes historically associated with adjustable gastric banding and laparoscopic sleeve gastrectomy, and some patients at higher starting weights achieve outcomes comparable to Roux-en-Y gastric bypass. This has led many clinicians and researchers to describe Mounjaro as bridging the gap between lifestyle intervention and bariatric surgery.
Start Your Weight Loss Journey With Mounjaro
GPhC-registered pharmacy (No. 9012585) · UK-licensed prescribers · Free online assessment · Superintendent Pharmacist: Palvinder Deol · Trustpilot 4.8 ★
Check Your Eligibility →
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. | Tirzepatide once a week for obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626. | Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. | Tirzepatide as compared with semaglutide (SURMOUNT-5). N Engl J Med. 2025. | NICE TA1026. Tirzepatide for managing overweight and obesity. 2024. | MHRA. Mounjaro (tirzepatide) prescribing information. 2023. | GPhC. Standards for registered pharmacies. 2023. | Happy Pharmacy (GPhC No. 9012585). Educational purposes only — not a substitute for individualised clinical assessment.